US6228879B1
(en)
*
|
1997-10-16 |
2001-05-08 |
The Children's Medical Center |
Methods and compositions for inhibition of angiogenesis
|
US6429221B1
(en)
|
1994-12-30 |
2002-08-06 |
Celgene Corporation |
Substituted imides
|
US5635517B1
(en)
*
|
1996-07-24 |
1999-06-29 |
Celgene Corp |
Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
|
HU228769B1
(en)
*
|
1996-07-24 |
2013-05-28 |
Celgene Corp |
Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
|
US7629360B2
(en)
*
|
1999-05-07 |
2009-12-08 |
Celgene Corporation |
Methods for the treatment of cachexia and graft v. host disease
|
US6458810B1
(en)
|
2000-11-14 |
2002-10-01 |
George Muller |
Pharmaceutically active isoindoline derivatives
|
DE60130799T2
(de)
*
|
2000-11-30 |
2008-07-17 |
Children's Medical Center Corp., Boston |
Synthese von 4-aminothalidomid enantiomeren
|
US20030045552A1
(en)
*
|
2000-12-27 |
2003-03-06 |
Robarge Michael J. |
Isoindole-imide compounds, compositions, and uses thereof
|
DE10137163A1
(de)
*
|
2001-07-30 |
2003-02-13 |
Bayer Ag |
Substituierte Isoindole und ihre Verwendung
|
DE60231989D1
(de)
*
|
2001-08-06 |
2009-05-28 |
Childrens Medical Center |
Antiangiogenese wirkung von stickstoffsubstituierten thalidomid-analoga
|
EP1475632B1
(en)
*
|
2002-02-14 |
2013-05-22 |
Ajinomoto Co., Inc. |
Method of analyzing aminofunctional compound and analytical reagent
|
CA2481387A1
(en)
*
|
2002-04-12 |
2003-10-23 |
Celgene Corporation |
Methods for identification of modulators of angiogenesis, compounds discovered thereby, and methods of treatment using the compounds
|
US7498171B2
(en)
|
2002-04-12 |
2009-03-03 |
Anthrogenesis Corporation |
Modulation of stem and progenitor cell differentiation, assays, and uses thereof
|
US7393862B2
(en)
|
2002-05-17 |
2008-07-01 |
Celgene Corporation |
Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
|
NZ549175A
(en)
|
2002-05-17 |
2007-12-21 |
Celgene Corp |
Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
|
US7968569B2
(en)
|
2002-05-17 |
2011-06-28 |
Celgene Corporation |
Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
US7323479B2
(en)
*
|
2002-05-17 |
2008-01-29 |
Celgene Corporation |
Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
|
AU2006202316B2
(en)
*
|
2002-05-17 |
2008-04-10 |
Celgene Corporation |
Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
|
USRE48890E1
(en)
|
2002-05-17 |
2022-01-11 |
Celgene Corporation |
Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation
|
EP1900369A1
(en)
|
2002-10-15 |
2008-03-19 |
Celgene Corporation |
Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes
|
US8404717B2
(en)
*
|
2002-10-15 |
2013-03-26 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes using lenalidomide
|
US7189740B2
(en)
*
|
2002-10-15 |
2007-03-13 |
Celgene Corporation |
Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
|
US11116782B2
(en)
|
2002-10-15 |
2021-09-14 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
|
US8404716B2
(en)
|
2002-10-15 |
2013-03-26 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
|
US20050203142A1
(en)
*
|
2002-10-24 |
2005-09-15 |
Zeldis Jerome B. |
Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
|
BR0315609A
(pt)
*
|
2002-10-24 |
2005-08-23 |
Celgene Corp |
Método de tratar, prevenir, modificar ou controlar dor e composição farmacêutica
|
US7563810B2
(en)
*
|
2002-11-06 |
2009-07-21 |
Celgene Corporation |
Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
|
US8034831B2
(en)
|
2002-11-06 |
2011-10-11 |
Celgene Corporation |
Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
|
KR101042448B1
(ko)
*
|
2002-11-26 |
2011-06-16 |
안트로제네시스 코포레이션 |
세포요법제, 세포요법제 단위 및 이를 이용한 치료방법
|
US7399866B2
(en)
*
|
2003-01-14 |
2008-07-15 |
Cytokinetics, Inc. |
Compounds, compositions, and methods
|
AU2004212009B2
(en)
*
|
2003-02-13 |
2010-07-29 |
Celularity Inc. |
Use of umbilical cord blood to treat individuals having a disease, disorder or condition
|
US7320992B2
(en)
*
|
2003-08-25 |
2008-01-22 |
Amgen Inc. |
Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
|
UA83504C2
(en)
|
2003-09-04 |
2008-07-25 |
Селджин Корпорейшн |
Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
JP4943845B2
(ja)
*
|
2003-09-17 |
2012-05-30 |
ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンティッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
サリドマイド類似体
|
US8952895B2
(en)
|
2011-06-03 |
2015-02-10 |
Apple Inc. |
Motion-based device operations
|
US7612096B2
(en)
*
|
2003-10-23 |
2009-11-03 |
Celgene Corporation |
Methods for treatment, modification and management of radiculopathy using 1-oxo-2-(2,6-dioxopiperidin-3yl)-4-aminoisoindoline
|
US20050100529A1
(en)
*
|
2003-11-06 |
2005-05-12 |
Zeldis Jerome B. |
Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
|
US20070208057A1
(en)
*
|
2003-11-06 |
2007-09-06 |
Zeldis Jerome B |
Methods And Compositions Using Thalidomide For The Treatment And Management Of Cancers And Other Diseases
|
CN101966183A
(zh)
*
|
2003-12-02 |
2011-02-09 |
细胞基因公司 |
用于治疗和控制血红蛋白病和贫血病的方法和组合物
|
US20050143344A1
(en)
*
|
2003-12-30 |
2005-06-30 |
Zeldis Jerome B. |
Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases
|
EP1737453A4
(en)
*
|
2004-03-22 |
2008-11-26 |
Celgene Corp |
METHOD FOR THE USE OF IMMUNOMODULATORY COMPOUNDS AND COMPOSITIONS CONTAINING THEREOF FOR THE TREATMENT AND SUPPLY OF SKIN DISEASES OR DISORDERS
|
US20050222209A1
(en)
*
|
2004-04-01 |
2005-10-06 |
Zeldis Jerome B |
Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
|
EA014429B1
(ru)
*
|
2004-04-14 |
2010-12-30 |
Селджин Корпорейшн |
Композиции, содержащие иммуномодулирующие соединения для лечения и управления течением миелодиспластических синдромов, и способы с их использованием
|
JP2007533761A
(ja)
*
|
2004-04-23 |
2007-11-22 |
セルジーン・コーポレーション |
肺高血圧症を治療し管理するための、免疫調節性化合物の使用方法及び免疫調節性化合物を含む組成物
|
JP2005336157A
(ja)
*
|
2004-04-30 |
2005-12-08 |
Arigen Inc |
光学活性サリドマイドおよびその誘導体の製造法
|
EP1746995A4
(en)
*
|
2004-05-05 |
2010-03-31 |
Celgene Corp |
METHOD OF USE AND COMPOSITIONS COMPRISING IMMUNOMODULATORY COMPOUNDS FOR THE TREATMENT AND MANAGEMENT OF MYELOPROLIFERATIVE DISEASES
|
DK1765327T3
(da)
|
2004-06-17 |
2014-11-03 |
Cytokinetics Inc |
Forbindelser, sammensætninger og fremgangsmåder
|
US7176222B2
(en)
|
2004-07-27 |
2007-02-13 |
Cytokinetics, Inc. |
Syntheses of ureas
|
BRPI0514865A
(pt)
*
|
2004-09-03 |
2008-06-24 |
Celgene Corp |
processo para preparar um composto
|
KR20070085454A
(ko)
*
|
2004-10-28 |
2007-08-27 |
셀진 코포레이션 |
중추신경계 손상의 치료 및 관리를 위하여 pde4조절제를 사용하는 방법 및 조성물
|
WO2006053160A2
(en)
*
|
2004-11-12 |
2006-05-18 |
Celgene Corporation |
Methods and compositions using immunomodulatory compounds for treatment and management of parasitic diseases
|
AU2005309733A1
(en)
*
|
2004-11-23 |
2006-06-01 |
Celgene Corporation |
Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury
|
US20060270707A1
(en)
*
|
2005-05-24 |
2006-11-30 |
Zeldis Jerome B |
Methods and compositions using 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione for the treatment or prevention of cutaneous lupus
|
CN102643267B
(zh)
*
|
2005-06-30 |
2015-09-16 |
细胞基因公司 |
4-氨基-2-(2,6-二氧哌啶-3-基)异吲哚啉-1,3-二酮化合物的制备方法
|
AU2006265601A1
(en)
*
|
2005-06-30 |
2007-01-11 |
Anthrogenesis Corporation |
Repair of tympanic membrane using placenta derived collagen biofabric
|
WO2007009062A2
(en)
*
|
2005-07-13 |
2007-01-18 |
Anthrogenesis Corporation |
Treatment of leg ulcers using placenta derived collagen biofabric
|
EP1919365A2
(en)
*
|
2005-07-13 |
2008-05-14 |
Anthrogenesis Corporation |
Ocular plug formed from placenta derived collagen biofabric
|
US7538223B2
(en)
|
2005-08-04 |
2009-05-26 |
Cytokinetics, Inc. |
Compounds, compositions and methods
|
MX2008002765A
(es)
*
|
2005-08-31 |
2008-04-07 |
Celgene Corp |
Compuestos de isoindol-imida y composiciones que la comprenden y metodos para usar los mismos.
|
CA2621136C
(en)
|
2005-09-01 |
2014-10-14 |
Celgene Corporation |
Immunological uses of immunomodulatory compounds for vaccine and anti-infectious disease therapy
|
US20070066512A1
(en)
|
2005-09-12 |
2007-03-22 |
Dominique Verhelle |
Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels
|
CN1939922B
(zh)
*
|
2005-09-27 |
2010-10-13 |
天津和美生物技术有限公司 |
可抑制细胞释放肿瘤坏死因子的5H-噻吩[3,4-c]吡咯-4,6-二酮衍生物
|
EP1957633B1
(en)
|
2005-10-13 |
2013-12-18 |
Anthrogenesis Corporation |
Immunomodulation using placental stem cells
|
US7825120B2
(en)
*
|
2005-12-15 |
2010-11-02 |
Cytokinetics, Inc. |
Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
|
ES2419007T3
(es)
*
|
2005-12-15 |
2013-08-19 |
Cytokinetics, Inc. |
Ciertas entidades químicas, composiciones y procedimientos
|
US20070208000A1
(en)
*
|
2005-12-15 |
2007-09-06 |
Morgan Bradley P |
Certain chemical entities, compositions and methods
|
EP1959947A2
(en)
*
|
2005-12-15 |
2008-08-27 |
Cytokinetics, Inc. |
Certain chemical entities, compositions and methods
|
EP1959962A2
(en)
*
|
2005-12-16 |
2008-08-27 |
Cytokinetics, Inc. |
Certain chemical entities, compositions, and methods
|
WO2007078839A2
(en)
*
|
2005-12-19 |
2007-07-12 |
Cytokinetics, Inc. |
Compounds, compositions and methods
|
US20070155791A1
(en)
*
|
2005-12-29 |
2007-07-05 |
Zeldis Jerome B |
Methods for treating cutaneous lupus using aminoisoindoline compounds
|
CA2633980A1
(en)
*
|
2005-12-29 |
2007-07-12 |
Anthrogenesis Corporation |
Improved composition for collecting and preserving placental stem cells and methods of using the composition
|
CN103146640B
(zh)
|
2005-12-29 |
2015-09-09 |
人类起源公司 |
胎盘干细胞群
|
US8247582B2
(en)
*
|
2006-02-07 |
2012-08-21 |
Battelle Memorial Institute |
Esters of 5-hydroxymethylfurfural and methods for their preparation
|
WO2007136640A2
(en)
*
|
2006-05-16 |
2007-11-29 |
Celgene Corporation |
Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
|
TW200806625A
(en)
*
|
2006-05-26 |
2008-02-01 |
Astrazeneca Ab |
Therapeutic compounds
|
EP2049119A2
(en)
*
|
2006-06-29 |
2009-04-22 |
Astex Therapeutics Limited |
Pharmaceutical combinations of 1-cyclopropyl-3-[3-(5-morphoolin-4-ylmethyl-1h-benzoimidazol-2-yl)-1h-1-pyrazol-4-yl]-urea
|
CL2007002218A1
(es)
*
|
2006-08-03 |
2008-03-14 |
Celgene Corp Soc Organizada Ba |
Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa.
|
US7993918B2
(en)
|
2006-08-04 |
2011-08-09 |
Anthrogenesis Corporation |
Tumor suppression using placental stem cells
|
WO2008021391A1
(en)
*
|
2006-08-15 |
2008-02-21 |
Anthrogenesis Corporation |
Umbilical cord biomaterial for medical use
|
US8877780B2
(en)
*
|
2006-08-30 |
2014-11-04 |
Celgene Corporation |
5-substituted isoindoline compounds
|
RU2448101C2
(ru)
*
|
2006-08-30 |
2012-04-20 |
Селджин Корпорейшн |
5-замещенные изоиндолиновые соединения
|
NZ575061A
(en)
*
|
2006-08-30 |
2011-10-28 |
Celgene Corp |
5-substituted isoindoline compounds
|
NZ575689A
(en)
*
|
2006-09-15 |
2011-12-22 |
Celgene Corp |
N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same
|
US20080131522A1
(en)
*
|
2006-10-03 |
2008-06-05 |
Qing Liu |
Use of placental biomaterial for ocular surgery
|
US8071135B2
(en)
|
2006-10-04 |
2011-12-06 |
Anthrogenesis Corporation |
Placental tissue compositions
|
CN104623643A
(zh)
|
2006-10-06 |
2015-05-20 |
人类起源公司 |
天然(端肽)胎盘胶原组合物
|
CA2677679A1
(en)
*
|
2007-02-12 |
2008-08-21 |
Anthrogenesis Corporation |
Hepatocytes and chondrocytes from adherent placental stem cells; and cd34+, cd45- placental stem cell-enriched cell populations
|
NZ578819A
(en)
*
|
2007-02-12 |
2012-02-24 |
Anthrogenesis Corp |
Treatment of inflammatory diseases using placental stem cells
|
NZ599199A
(en)
*
|
2007-03-20 |
2013-10-25 |
Celgene Corp |
4'-o-substituted isoindoline derivatives and compositions comprising and methods of using the same
|
US20100172830A1
(en)
*
|
2007-03-29 |
2010-07-08 |
Cellx Inc. |
Extraembryonic Tissue cells and method of use thereof
|
US7893045B2
(en)
|
2007-08-07 |
2011-02-22 |
Celgene Corporation |
Methods for treating lymphomas in certain patient populations and screening patients for said therapy
|
CN101978045A
(zh)
*
|
2007-09-26 |
2011-02-16 |
细胞基因细胞疗法公司 |
来自人胎盘灌洗液的血管生成细胞
|
US8492395B2
(en)
|
2007-09-26 |
2013-07-23 |
Celgene Corporation |
7-substituted quinazolinone compounds and compositions comprising the same
|
ES2530995T3
(es)
|
2007-09-28 |
2015-03-09 |
Anthrogenesis Corp |
Supresión de tumor usando perfusato placentario humano y células asesinas naturales intermediarias que provienen de placenta humana
|
NO2217329T3
(US20030045552A1-20030306-C00278.png)
*
|
2007-11-07 |
2018-06-09 |
|
|
AU2008325140A1
(en)
*
|
2007-11-08 |
2009-05-14 |
Celgene Corporation |
Use of immunomodulatory compounds for the treatment of disorders associated with endothelial dysfunction
|
WO2009073146A2
(en)
*
|
2007-11-29 |
2009-06-11 |
Celgene Corporation |
Use of immunomodulatory compounds for the treatment of transverse myelitis, multiple sclerosis, and other disorders
|
WO2009085234A2
(en)
|
2007-12-20 |
2009-07-09 |
Signal Pharmaceuticals, Inc. |
Use of micro-rna as a biomarker of immunomodulatory drug activity
|
CA2712724A1
(en)
*
|
2008-01-29 |
2009-08-06 |
Celgene Corporation |
Use of lenalidomide or pomalidomide for treating a disease associated with cd59 deficiency
|
WO2009105256A2
(en)
*
|
2008-02-20 |
2009-08-27 |
Celgene Corporation |
Method of treating cancer by administering an immunomodulatory compound in combination with a cd40 antibody or cd40 ligand
|
US10104880B2
(en)
*
|
2008-08-20 |
2018-10-23 |
Celularity, Inc. |
Cell composition and methods of making the same
|
DK2329012T3
(da)
*
|
2008-08-20 |
2020-08-24 |
Celularity Inc |
Behandling af slagtilfælde under anvendelse af isolerede placentaceller
|
MX339068B
(es)
*
|
2008-08-22 |
2016-05-10 |
Anthrogenesis Corp |
Metodos y composiciones para el tratamiento de defectos oseos con poblaciones de celulas placentarias.
|
PL2358697T3
(pl)
*
|
2008-10-29 |
2016-04-29 |
Celgene Corp |
Związki izoindolinowe do zastosowania w leczeniu raka
|
NZ602455A
(en)
*
|
2008-11-19 |
2014-03-28 |
Anthrogenesis Corp |
Amnion derived adherent cells
|
AU2009316376B2
(en)
*
|
2008-11-21 |
2015-08-20 |
Celularity Inc. |
Treatment of diseases, disorders or conditions of the lung using placental cells
|
WO2010077686A1
(en)
*
|
2008-12-08 |
2010-07-08 |
Sirtris Pharmaceuticals, Inc. |
Isoindolinone and related analogs as sirtuin modulators
|
EP2411506B1
(en)
|
2009-03-25 |
2018-11-07 |
Celularity, Inc. |
Tumor suppression using human placenta-derived intermediate natural killer cells and immunomodulatory compounds
|
WO2010137547A1
(ja)
|
2009-05-25 |
2010-12-02 |
国立大学法人東京工業大学 |
中枢神経細胞の増殖及び分化に係る中核因子を含む医薬組成物
|
CN101580501B
(zh)
|
2009-06-01 |
2011-03-09 |
南京卡文迪许生物工程技术有限公司 |
3-(取代二氢异吲哚酮-2-基)-2,6-哌啶二酮的合成方法及其中间体
|
US9226913B2
(en)
|
2010-01-05 |
2016-01-05 |
Celgene Corporation |
Methods of treating cancer using a combination of an immunomodulatory compound and an artemisinin or a derivative thereof
|
US9121007B2
(en)
*
|
2010-01-26 |
2015-09-01 |
Anthrogenesis Corporatin |
Treatment of bone-related cancers using placental stem cells
|
SI2536706T1
(sl)
|
2010-02-11 |
2017-10-30 |
Celgene Corporation |
Derivati arilmetoksi izoindolina in sestavki,ki jih vsebujejo ter metode uporabe le-teh
|
MX341050B
(es)
|
2010-04-07 |
2016-08-05 |
Celgene Corp * |
Metodos para tratar infeccion viral respiratoria.
|
KR20190076060A
(ko)
|
2010-04-07 |
2019-07-01 |
안트로제네시스 코포레이션 |
태반 줄기 세포를 사용한 혈관신생
|
US8562973B2
(en)
|
2010-04-08 |
2013-10-22 |
Anthrogenesis Corporation |
Treatment of sarcoidosis using placental stem cells
|
EP2593542B1
(en)
|
2010-07-13 |
2018-01-03 |
Anthrogenesis Corporation |
Methods of generating natural killer cells
|
WO2012078492A1
(en)
|
2010-12-06 |
2012-06-14 |
Celgene Corporation |
A combination therapy with lenalidomide and a cdk inhibitor for treating multiple myeloma
|
AU2011352036A1
(en)
|
2010-12-31 |
2013-07-18 |
Anthrogenesis Corporation |
Enhancement of placental stem cell potency using modulatory RNA molecules
|
KR20140014221A
(ko)
|
2011-03-11 |
2014-02-05 |
셀진 코포레이션 |
3-(5-아미노-2-메틸-4-옥소-4h-퀴나졸린-3-일)-피페리딘-2,6-디온의 고체 형태, 및 그의 제약 조성물 및 용도
|
CA2867134C
(en)
|
2011-03-28 |
2019-05-07 |
Sheila Dewitt |
2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds
|
CA2833348A1
(en)
|
2011-04-18 |
2012-10-26 |
Celgene Corporation |
Biomarkers for the treatment of multiple myeloma
|
KR20140024914A
(ko)
|
2011-04-29 |
2014-03-03 |
셀진 코포레이션 |
예측인자로 세레브론을 사용하는 암 및 염증성 질환의 치료를 위한 방법
|
US9040035B2
(en)
|
2011-06-01 |
2015-05-26 |
Anthrogenesis Corporation |
Treatment of pain using placental stem cells
|
US8927725B2
(en)
|
2011-12-02 |
2015-01-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Thio compounds
|
US10335482B2
(en)
|
2012-06-06 |
2019-07-02 |
Bionor Immuno As |
Method of inducing an anti-HIV-1 immune response comprising administering a C5/TM-GP41 peptide dimer
|
JP6318152B2
(ja)
|
2012-06-29 |
2018-04-25 |
セルジーン コーポレイション |
セレブロン関連タンパク質を利用して薬物効能を決定する方法
|
US9587281B2
(en)
|
2012-08-14 |
2017-03-07 |
Celgene Corporation |
Cereblon isoforms and their use as biomarkers for therapeutic treatment
|
AU2013204922B2
(en)
|
2012-12-20 |
2015-05-14 |
Celgene Corporation |
Chimeric antigen receptors
|
AU2014205043B2
(en)
|
2013-01-14 |
2018-10-04 |
Deuterx, Llc |
3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
|
US9763983B2
(en)
|
2013-02-05 |
2017-09-19 |
Anthrogenesis Corporation |
Natural killer cells from placenta
|
US9290475B2
(en)
|
2013-03-14 |
2016-03-22 |
Deuterx, Llc |
3-(substituted-4-oxoquinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same
|
CN105518018B
(zh)
|
2013-03-15 |
2020-04-03 |
细胞基因公司 |
修饰的t淋巴细胞
|
WO2015007337A1
(en)
|
2013-07-19 |
2015-01-22 |
Bionor Immuno As |
Method for the vaccination against hiv
|
CN103396397A
(zh)
*
|
2013-08-14 |
2013-11-20 |
中国人民解放军军事医学科学院毒物药物研究所 |
来那度胺衍生物及其作为药物的用途
|
CN103421061A
(zh)
*
|
2013-08-14 |
2013-12-04 |
中国药科大学 |
来那度胺衍生物、其制法及其医药用途
|
EP3087069B1
(en)
*
|
2013-12-23 |
2019-01-30 |
Norgine B.V. |
Compounds useful as ccr9 modulators
|
JP6778114B2
(ja)
*
|
2014-04-14 |
2020-10-28 |
アルビナス・オペレーションズ・インコーポレイテッドArvinas Operations, Inc. |
イミド系タンパク質分解モジュレーター及び関連する使用方法
|
EP3160486B1
(en)
|
2014-06-27 |
2020-11-18 |
Celgene Corporation |
Compositions and methods for inducing conformational changes in cereblon other e3 ubiquitin ligases
|
WO2016005508A1
(en)
|
2014-07-11 |
2016-01-14 |
Bionor Immuno As |
Method for reducing and/or delaying pathological effects of human immunodeficiency virus i (hiv) or for reducing the risk of developing acquired immunodeficiency syndrome (aids)
|
PL3182996T3
(pl)
|
2014-08-22 |
2023-04-17 |
Celgene Corporation |
Sposoby leczenia szpiczaka mnogiego związkami immunomodulującymi w kombinacji z przeciwciałami
|
US10017492B2
(en)
*
|
2014-10-30 |
2018-07-10 |
Kangpu Biopharmaceuticals, Ltd. |
Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof
|
EP3256470B1
(en)
*
|
2014-12-23 |
2023-07-26 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
US9694084B2
(en)
|
2014-12-23 |
2017-07-04 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
KR20220029783A
(ko)
|
2015-01-20 |
2022-03-08 |
아비나스 오퍼레이션스, 인코포레이티드 |
안드로겐 수용체의 표적화된 분해를 위한 화합물 및 방법
|
US20170327469A1
(en)
|
2015-01-20 |
2017-11-16 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
WO2016177833A1
(en)
|
2015-05-04 |
2016-11-10 |
Bionor Immuno As |
Dosage regimen for hiv vaccine
|
EP3302482A4
(en)
|
2015-06-05 |
2018-12-19 |
Arvinas, Inc. |
Tank-binding kinase-1 protacs and associated methods of use
|
WO2016210262A1
(en)
|
2015-06-26 |
2016-12-29 |
Celgene Corporation |
Methods for the treatment of kaposi's sarcoma or kshv-induced lymphoma using immunomodulatory compounds, and uses of biomarkers
|
US9809603B1
(en)
|
2015-08-18 |
2017-11-07 |
Deuterx, Llc |
Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same
|
US10772962B2
(en)
|
2015-08-19 |
2020-09-15 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of bromodomain-containing proteins
|
WO2017054739A1
(zh)
*
|
2015-09-29 |
2017-04-06 |
康朴生物医药技术(上海)有限公司 |
一种药物组合物及其应用
|
WO2017117118A1
(en)
|
2015-12-28 |
2017-07-06 |
Celgene Corporation |
Compositions and methods for inducing conformational changes in cereblon and other e3 ubiquitin ligases
|
AU2017246452C1
(en)
*
|
2016-04-06 |
2021-06-03 |
The Regents Of The University Of Michigan |
MDM2 protein degraders
|
WO2017176958A1
(en)
*
|
2016-04-06 |
2017-10-12 |
The Regents Of The University Of Michigan |
Monofunctional intermediates for ligand-dependent target protein degradation
|
BR112018070859A2
(pt)
*
|
2016-04-12 |
2019-02-05 |
Univ Michigan Regents |
degradantes da proteína de bet
|
CN109562113A
(zh)
|
2016-05-10 |
2019-04-02 |
C4医药公司 |
用于靶蛋白降解的螺环降解决定子体
|
WO2017197046A1
(en)
|
2016-05-10 |
2017-11-16 |
C4 Therapeutics, Inc. |
C3-carbon linked glutarimide degronimers for target protein degradation
|
EP3454856A4
(en)
|
2016-05-10 |
2019-12-25 |
C4 Therapeutics, Inc. |
HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN REDUCTION
|
PL3660004T3
(pl)
|
2016-10-11 |
2023-10-02 |
Arvinas Operations, Inc. |
Związki i sposoby do ukierunkowanej degradacji receptora androgenowego
|
JP7286539B2
(ja)
|
2016-11-01 |
2023-06-05 |
アルビナス・オペレーションズ・インコーポレイテッド |
タウタンパク質標的化protac、および関連使用方法
|
RU2750484C2
(ru)
|
2016-12-01 |
2021-06-28 |
Эрвинэс Оперейшнс, Инк. |
Производные тетрагидронафталина и тетрагидроизохинолина в качестве разрушителей эстрогенового рецептора
|
CN110248678A
(zh)
|
2016-12-03 |
2019-09-17 |
朱诺治疗学股份有限公司 |
调节car-t细胞的方法
|
US20200078400A1
(en)
|
2016-12-03 |
2020-03-12 |
Juno Therapeutics, Inc. |
Methods for determining car-t cells dosing
|
JP7048106B2
(ja)
*
|
2016-12-16 |
2022-04-05 |
カンプ・バイオファーマスーティカルズ、リミテッド |
組み合わせ、その用途及び処置方法
|
EP3559006A4
(en)
|
2016-12-23 |
2021-03-03 |
Arvinas Operations, Inc. |
COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF FETAL LIVER KINASE POLYPEPTIDES
|
CN110741004B
(zh)
|
2016-12-23 |
2023-10-17 |
阿尔维纳斯运营股份有限公司 |
用于迅速加速性纤维肉瘤多肽的靶向降解的化合物和方法
|
CN110753693A
(zh)
|
2016-12-23 |
2020-02-04 |
阿尔维纳斯运营股份有限公司 |
Egfr蛋白水解靶向嵌合分子和相关使用方法
|
US11191741B2
(en)
|
2016-12-24 |
2021-12-07 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
|
MX2019008934A
(es)
|
2017-01-26 |
2019-11-05 |
Arvinas Operations Inc |
Moduladores de la proteolisis del receptor de estrogeno y métodos asociados de uso,.
|
KR102125661B1
(ko)
*
|
2017-02-13 |
2020-06-22 |
강푸 바이오파마슈티칼즈 리미티드 |
전립선암 치료용 조합, 약학 조성물 및 치료 방법
|
WO2018204427A1
(en)
|
2017-05-01 |
2018-11-08 |
Juno Therapeutics, Inc. |
Combination of a cell therapy and an immunomodulatory compound
|
US10093647B1
(en)
|
2017-05-26 |
2018-10-09 |
Celgene Corporation |
Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione dihydrate, compositions and methods of use thereof
|
JP2020522489A
(ja)
|
2017-06-02 |
2020-07-30 |
ジュノー セラピューティクス インコーポレイテッド |
養子細胞療法を用いる処置のための製造物品および方法
|
WO2018237026A1
(en)
|
2017-06-20 |
2018-12-27 |
C4 Therapeutics, Inc. |
N / O-LINKED DEGRONS AND DEGRONIMERS FOR DEGRADATION OF PROTEINS
|
AU2018291032A1
(en)
|
2017-06-29 |
2020-01-16 |
Juno Therapeutics, Inc. |
Mouse model for assessing toxicities associated with immunotherapies
|
CN109422751B
(zh)
*
|
2017-09-03 |
2022-04-22 |
上海美志医药科技有限公司 |
一类具有降解酪氨酸蛋白激酶jak3活性的化合物
|
CN111315735B
(zh)
|
2017-09-04 |
2024-03-08 |
C4医药公司 |
二氢苯并咪唑酮
|
WO2019043208A1
(en)
|
2017-09-04 |
2019-03-07 |
F. Hoffmann-La Roche Ag |
DIHYDROQUINOLINONES
|
CN111278815B
(zh)
|
2017-09-04 |
2024-03-08 |
C4医药公司 |
戊二酰亚胺
|
US10093648B1
(en)
|
2017-09-22 |
2018-10-09 |
Celgene Corporation |
Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione hemihydrate, compositions and methods of use thereof
|
US10093649B1
(en)
|
2017-09-22 |
2018-10-09 |
Celgene Corporation |
Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione monohydrate, compositions and methods of use thereof
|
US20200246393A1
(en)
|
2017-09-28 |
2020-08-06 |
Celularity, Inc. |
Tumor suppression using human placenta-derived intermediate natural killer (pink) cells in combination with an antibody
|
EP3703688A2
(en)
|
2017-11-01 |
2020-09-09 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
|
US20210132042A1
(en)
|
2017-11-01 |
2021-05-06 |
Juno Therapeutics, Inc. |
Methods of assessing or monitoring a response to a cell therapy
|
EP3710002A4
(en)
|
2017-11-16 |
2021-07-07 |
C4 Therapeutics, Inc. |
DEGRADER AND DEGRONE FOR TARGETED PROTEIN DEGRADATION
|
EP3710443A1
(en)
|
2017-11-17 |
2020-09-23 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
|
MA51210A
(fr)
|
2017-12-01 |
2020-10-07 |
Juno Therapeutics Inc |
Procédés de dosage et de modulation de cellules génétiquement modifiées
|
MA51184A
(fr)
|
2017-12-15 |
2020-10-21 |
Juno Therapeutics Inc |
Molécules de liaison à l'anti-cct5 et procédés d'utilisation associés
|
CN111655685B
(zh)
*
|
2018-01-25 |
2023-11-17 |
藤本株式会社 |
噻吩衍生物及其用途
|
JP2021512153A
(ja)
|
2018-01-26 |
2021-05-13 |
イエール ユニバーシティ |
タンパク質分解のイミド系モジュレーターおよび使用方法
|
JP2021514193A
(ja)
|
2018-02-21 |
2021-06-10 |
セルジーン コーポレイション |
Bcma結合抗体及びその使用
|
EP3773576A4
(en)
|
2018-03-26 |
2021-12-29 |
C4 Therapeutics, Inc. |
Cereblon binders for the degradation of ikaros
|
KR20230130752A
(ko)
|
2018-04-04 |
2023-09-12 |
아비나스 오퍼레이션스, 인코포레이티드 |
단백질분해 조절제 및 연관된 사용 방법
|
WO2019204354A1
(en)
|
2018-04-16 |
2019-10-24 |
C4 Therapeutics, Inc. |
Spirocyclic compounds
|
ES2959622T3
(es)
|
2018-04-23 |
2024-02-27 |
Celgene Corp |
Compuestos de 4-aminoisoindolina-1,3-diona sustituidos y su uso para tratar el linfoma
|
EP3578561A1
(en)
|
2018-06-04 |
2019-12-11 |
F. Hoffmann-La Roche AG |
Spiro compounds
|
CN112638380A
(zh)
*
|
2018-06-29 |
2021-04-09 |
达纳-法伯癌症研究所有限公司 |
小脑蛋白(crbn)配体
|
WO2020051235A1
(en)
*
|
2018-09-04 |
2020-03-12 |
C4 Therapeutics, Inc. |
Compounds for the degradation of brd9 or mth1
|
JP2022512971A
(ja)
|
2018-11-08 |
2022-02-07 |
ジュノー セラピューティクス インコーポレイテッド |
処置およびt細胞調節のための方法および併用
|
WO2020102195A1
(en)
*
|
2018-11-13 |
2020-05-22 |
Biotheryx, Inc. |
Substituted isoindolinones
|
MX2021005734A
(es)
|
2018-11-16 |
2021-09-10 |
Juno Therapeutics Inc |
Metodos de dosificacion de celulas t modificadas para el tratamiento de malignidades de celulas b.
|
WO2020113194A2
(en)
|
2018-11-30 |
2020-06-04 |
Juno Therapeutics, Inc. |
Methods for treatment using adoptive cell therapy
|
CN109293631B
(zh)
*
|
2018-11-30 |
2020-05-08 |
常州制药厂有限公司 |
3-氨基-n-(2,6-二氧代-3-哌啶基)-邻苯二甲酰亚胺化合物的制备方法
|
EP3917570A1
(en)
|
2019-01-29 |
2021-12-08 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1)
|
WO2020227183A1
(en)
*
|
2019-05-03 |
2020-11-12 |
Dynamic Biologics Inc. |
Lenalidomide prodrugs, polymeric conjugates, and formulations thereof, and their uses for the treatment of multiple myeloma
|
WO2020242960A1
(en)
|
2019-05-24 |
2020-12-03 |
Biotheryx, Inc. |
Compounds targeting proteins and pharmaceutical compositions thereof, and their therapeutic applications
|
WO2021069705A1
(en)
*
|
2019-10-09 |
2021-04-15 |
Monte Rosa Therapeutics |
Isoindolinone compounds
|
AU2020387392A1
(en)
|
2019-11-19 |
2022-07-14 |
Bristol-Myers Squibb Company |
Compounds useful as inhibitors of Helios protein
|
EP4077309A1
(en)
|
2019-12-19 |
2022-10-26 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
JP2024504932A
(ja)
|
2021-01-13 |
2024-02-02 |
モンテ ローザ セラピューティクス, インコーポレイテッド |
イソインドリノン化合物
|
CN112876414B
(zh)
*
|
2021-01-29 |
2022-09-09 |
河南大学 |
一种基于多胺修饰的萘酰亚胺缀合物、其制备方法及应用
|
WO2022200857A1
(en)
*
|
2021-03-22 |
2022-09-29 |
Monte Rosa Therapeutics Ag |
Pharmaceutical compositions for use in the prevention and treatment of a disease or disorder caused by or associated with one or more premature termination codons
|
IL307343A
(en)
|
2021-04-06 |
2023-11-01 |
Bristol Myers Squibb Co |
Pyridinyl substituted oxisoisoindoline compounds
|
EP4333836A1
(en)
*
|
2021-05-07 |
2024-03-13 |
Kymera Therapeutics, Inc. |
Deuterated irak degraders and uses thereof
|
CN115504963A
(zh)
*
|
2021-06-22 |
2022-12-23 |
苏州开拓药业股份有限公司 |
一种c-Myc蛋白降解剂
|
WO2023081224A1
(en)
*
|
2021-11-03 |
2023-05-11 |
St. Jude Children's Research Hospital, Inc. |
Substituted n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4- yl)methyl)benzamide analogs as modulators of cereblon protein
|
CN114656374A
(zh)
*
|
2022-02-22 |
2022-06-24 |
营口兴福化工有限公司 |
2,4-二氯-3-氰基-5-氟苯甲酸合成方法
|
WO2023250400A1
(en)
|
2022-06-22 |
2023-12-28 |
Juno Therapeutics, Inc. |
Treatment methods for second line therapy of cd19-targeted car t cells
|
KR20240001072A
(ko)
*
|
2022-06-24 |
2024-01-03 |
주식회사 아이비스바이오 |
신규한 포말리도마이드 유도체 및 이의 제조방법
|
WO2024054591A1
(en)
|
2022-09-07 |
2024-03-14 |
Arvinas Operations, Inc. |
Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use
|